Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Chinese Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, B. A.
NEUROLOGY 2008;71:S14-S20
© 2008 American Academy of Neurology

Identification, causation, alleviation, and prevention of complications (ICAP)

An approach to symptom and disability management in multiple sclerosis Bruce A. Cohen, MD

From the Northwestern Comprehensive, Multiple Sclerosis Program, Northwestern University, Chicago, Illinois.

Address correspondence and reprint requests to Dr. Bruce Cohen, Northwestern University Department of Neurology, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago, IL 60611 bac106{at}northwestern.edu

Comprehensive management of patients with multiple sclerosis (MS) includes treatment to modify the disease course and interventions to address the persistent symptoms and consequences of this chronic illness, which can affect patients for decades. Although much excitement and attention accompanies new therapeutic initiatives for disease management, symptomatic issues are often overshadowed despite their impact on patients' daily lives. This article describes the application of an organizational scheme of identification, causation, alleviation, and prevention of complications as a tool for identifying and managing symptomatic issues in patients with MS.

Disclosure: Sources of Funding for Research: BioMS Medical Corp.; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc. Consulting Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Pfizer Inc.; Teva Neurosciences, Inc. Speakers' Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Teva Neurosciences, Inc. Financial Interests/Stock Ownership: Abbott Laboratories.

Discussion of Off-Label, Investigational, or Experimental Drug Use: Off-label medications used to alleviate MS symptoms, including amantadine, modafinil, methylphenidate, selective serotonin reuptake inhibitors for MS fatigue, donepezil, mernantine, and {alpha}-1 antagonists such as tamsulosin, doxazosin, and terazosin, and botulinum toxin.

Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.